Peptide & Experimental
Dasatinib + Quercetin (senolytic stack)
Senolytic combination (tyrosine kinase inhibitor + flavonoid) · D+Q protocol
Dasatinib plus quercetin is the best-known senolytic protocol in the longevity scene: a few days of tablets, then nothing for weeks. In humans it is established that the combination removes senescent cells from tissue. Whether this turns into a noticeable benefit is something no controlled study has been able to show so far.
In short
D+Q combines a prescription-only cancer drug (dasatinib, approved for chronic myeloid leukemia) with a plant compound from onions and apples (quercetin). Together the two hit more types of senescent cells than either alone, hence the combination and hence the pulsed schedule. The mechanism is established in humans: after three days of tablets, fat tissue biopsies showed 35 percent fewer senescent cells, and there were fewer inflammatory substances in the blood. The catch is the next step: in both studies that had a control group alongside, the clinical benefit was smaller or could no longer be found at all. Dasatinib remains a cancer drug with a corresponding side effect profile; for senolytic use there is no approval and no safety database.
What senescent cells are
Aging cells eventually stop dividing. But they do not die. They remain in the tissue and continuously release inflammatory substances. In technical language they are called senescent cells; online, zombie cells.
This leads to a simple idea: these cells do not need to be repaired, only removed. Substances that do this are called senolytics. Dasatinib plus quercetin is the most extensively studied combination in this class.
The starting point for the field is a 2016 paper: mice in which senescent cells can be killed via a built-in genetic switch. Switched twice a week from the first year of life onward, median lifespan rose by 27 percent in one mouse strain and 24 percent in the other. Kidney, heart and fat tissue aged more slowly.
Why two substances and why pulsed
Dasatinib is a tyrosine kinase inhibitor and is approved in Europe for leukemia. Quercetin is a flavonoid from onions and apples, freely available as a capsule. Senescent cells depend on certain survival pathways, and the two substances attack different ones. Individually, each only hits certain cell types; together they cover more.
This also explains the unusual intake schedule. Once the cells have been removed, they take weeks to accumulate again. So there is no need for daily dosing, only short bursts. In technical language the principle is called hit and run. And it explains why quercetin alone is not the protocol.
What is well supported
The most robust finding in the field is unspectacular and therefore often overlooked: the mechanism works in humans. In 2019 at the Mayo Clinic, nine people with diabetic kidney disease took the combination for three days, followed 11 days later by tissue samples. Senescent cells in fat tissue had decreased by 35 percent, another marker by 62 percent, and inflammatory macrophages by 28 percent. In the blood, interleukin 6, interleukin 1 alpha and two matrix metalloproteinases fell. There was no control group, but cell counts in a person’s own tissue before and after are comparatively robust. That is more than most longevity substances can show: not an advertising claim but a biopsy. The 6-month monkey study points in the same direction.
What the studies show
Diabetic kidney disease, 9 participants, 2019
Open-label study without a control group, three days of intake, tissue samples from fat and skin 11 days later. Result: 35 percent fewer senescent cells in fat tissue, another marker minus 62 percent, inflammatory macrophages minus 28 percent, plus fewer inflammatory substances in the blood. The proof that the substances do in humans what they are supposed to do.
Pulmonary fibrosis, open-label, 14 participants, 2019
Three days per week for three weeks, without blinding and without placebo. Afterwards, six-minute walking distance, gait speed and standing up from a chair were better, all statistically significant. This is the study that gets cited. Its problem: everyone knew who was getting what, and the endpoints depend on how hard someone tries.
Pulmonary fibrosis, randomized and blinded, 12 participants
The same group repeated the trial in the same disease with the same schedule, this time randomized, single-blind and with placebo. Physical function did not differ meaningfully between the groups. In the active group, 65 non-serious side effects were reported versus 22 under placebo, sleep disturbances and restlessness in 4 of 6 treated versus 0 of 6. This study is cited far less often than the open-label one.
Alzheimer’s disease, phase 1, 5 participants, 12 weeks
The question was not whether it helps, but whether the active substance reaches the brain at all. Dasatinib was detectable in the cerebrospinal fluid of 4 of 5 people, but only at about 0.5 percent of the blood level. Quercetin was not detectable at all. Anyone considering the protocol for cognition should know this measurement.
Bone metabolism, 60 women, 20 weeks, 2024
The largest study to date, randomized and with a control group, in postmenopausal women. The primary endpoint was missed: the bone resorption marker fell by 4.1 percent under D+Q and by 7.7 percent in the control group, p = 0.61. The bone formation marker rose by 16 percent in weeks 2 and 4 and had disappeared again by week 20. Different in the subgroup with the highest burden of senescent cells: bone formation plus 34 percent, bone resorption minus 11 percent, bone density at the forearm 2.7 percent higher after 20 weeks.
Middle-aged monkeys, 6 months
Nine treated animals versus seven control animals, 2 treatment days per month. Fewer senescence markers in fat tissue, anti-inflammatory shifts in immune cells, better kidney values, no serious side effects. Above all, a useful safety signal for the pulsed schedule.
Where the data stop
The benefit. Twice a control group stood alongside, twice the effect became smaller or disappeared: completely in pulmonary fibrosis, on the main question in bone metabolism. That is the normal case when open-label studies are repeated under controlled conditions. The two pulmonary fibrosis studies are a case in point: the open-label version makes headlines, the controlled one does not find the effect again and is hardly cited.
The mouse data also carry less far than they sound. There it was not a drug that acted but a built-in genetic switch, and maximum lifespan did not increase: the animals died less early, they did not live longer than was possible. It also remains open whether the subgroup signal in people with a high senescent cell burden is real. One reading: simply the wrong people were treated, and those who have many of these cells benefit more; the authors themselves suggest pre-selecting future study participants by this marker. The other reading: a subgroup analysis after a missed primary endpoint is exactly the point at which research most often deceives itself. Such a signal is a hypothesis for the next study, not a result. It can only be settled with a study that stratifies by senescent cell burden beforehand and then randomizes.
Status, approval and legal
Dasatinib is prescription-only and approved in Europe for chronic myeloid leukemia, brand name Sprycel. There is no approval for senolytic use. A doctor can nevertheless prescribe dasatinib outside its approval, that is, off label; this falls under the doctor’s responsibility and liability, and health insurance does not pay for it. What circulates in the scene often comes from abroad and without medical supervision. Quercetin alone is freely available, but it is precisely not the protocol. The material evaluated provides no information on doping relevance.
Safety
The safety information on dasatinib comes from continuous daily therapy in leukemia patients. The summary of product characteristics lists as very common, that is, in more than 1 in 10: pleural effusion, meaning fluid between the lung and the chest wall, bone marrow suppression with anemia and a shortage of white blood cells and platelets, plus bleeding. As uncommon, that is, rarer than 1 in 100: pulmonary arterial hypertension and a prolongation of the QT interval of the heart. The obvious objection is justified: a few pulse days per month in otherwise healthy people are something different from continuous dosing in patients. But no safety database exists for this use: 60 women over 20 weeks, a few dozen other people over a few weeks, 16 monkeys. Even in this thin data, more non-serious side effects occurred under the active substance than under placebo. Quercetin can also reduce iron absorption. Anyone with plans involving dasatinib belongs in a conversation with a doctor, not in a forum.
BK-Score Studied – no benefit shown
| Human evidence | 5 | |
|---|---|---|
| Mechanism | 7 | |
| Safety data | 4 | |
| Hype gap | 3 | |
| Track record of use | 2 |
Evidence 5: several studies are available in humans, but only two of them are randomized and controlled – 12 participants with pulmonary fibrosis and 60 women over 20 weeks –; the rest are uncontrolled series with 9, 14 and 5 participants, all designed around surrogate and functional markers. Mechanism 7: the target structure is confirmed in humans, not merely plausible – biopsies after 3 days of tablets showed 35 % fewer senescent cells in fat tissue, another marker −62 % and reduced inflammatory substances in the blood; the chain up to the clinical outcome, however, is not quantified. Safety 4: only short-term data for this use – 60 women over 20 weeks, a few dozen people over a few weeks, 16 monkeys; the dasatinib profile (pleural effusion, bone marrow suppression, bleeding) comes from continuous therapy in leukemia. Hype 3: the open-label pulmonary fibrosis study is cited, the controlled repeat with the null result hardly at all – a single finding becomes the overall message. Use 2: use only in studies and small gray-market circles; for aging there is no approval, only off-label prescription under a doctor’s responsibility. Direction negative: both times a placebo stood alongside, the benefit became smaller or disappeared – completely in pulmonary fibrosis, on the primary endpoint in bone metabolism (−4.1 % versus −7.7 %, p = 0.61).
The score rates the state of knowledge, not the substance. “Safety data 9” means well studied – not harmless.
Subjective assessment by Biohacking Kompakt based on published scoring rules – not a scientific rating and not a medical recommendation. Rules and all ratings (German)
Frequently asked questions about Dasatinib + Quercetin (senolytic stack)
Does dasatinib plus quercetin work against aging?
What is established is that the combination measurably reduces senescent cells and inflammatory substances in humans. What is not established is that a noticeable benefit follows from this. In the two studies with a control group, the clinical effect was smaller or no longer detectable at all.
Why is the combination taken on only a few days?
After being removed, senescent cells take weeks to accumulate again. Daily intake is therefore not necessary. The principle is called hit and run: strike briefly, then a long break.
Is quercetin alone enough?
Not according to the available data. Different senescent cells depend on different survival pathways, and that is exactly why the combination exists. The human studies were all, without exception, conducted with both substances together.
Does the protocol reach the brain?
Only partly. In a phase 1 study with 5 people, dasatinib was detectable in the cerebrospinal fluid of 4 of 5, but only at about 0.5 percent of the blood level. Quercetin was not detectable there at all.
Can a doctor in Germany prescribe the protocol?
Legally yes, but only as an off-label prescription: there is no approval for aging processes; dasatinib is prescription-only and approved for leukemia. If a doctor nevertheless prescribes it against aging, this falls under the doctor’s responsibility and liability, and health insurance does not cover the costs.
What is the better-supported alternative?
Anything that prevents senescent cells from arising in the first place is better studied than anything that removes them afterwards. Strength training, sufficient sleep and not smoking sound like calendar wisdom, but they have the better studies.
Related
- Mentioned togetherQuercetin
- Mentioned togetherFisetin
- Related topicFOXO4-DRI
- Same section5-Amino-1MQ
- Same sectionRapamycin (Sirolimus)
- Same sectionAdipotide (FTPP)
Sources
- Hickson LJ et al., EBioMedicine 2019 – senolytics in diabetic kidney disease
- Justice JN et al., EBioMedicine 2019 – open-label study in pulmonary fibrosis
- Baker DJ et al., Nature 2016 – genetic removal of senescent cells in mice
- Nambiar A et al., EBioMedicine 2023 – randomized, single-blind follow-up study in pulmonary fibrosis, 12 participants
- Gonzales MM et al., Nature Medicine 2023 – phase 1 study in Alzheimer’s disease
- Farr JN et al., Nature Medicine 2024 – bone metabolism, 60 women, 20 weeks
- Ruggiero AD et al., GeroScience 2023 – study in middle-aged monkeys, 6 months, 9 treated versus 7 controls
- Summary of product characteristics, dasatinib (Sprycel), European Medicines Agency
Open in the database – with search, filters and comparison (German app)
Information only, not medical advice and not a usage or dosage recommendation. Prescription-only and unapproved substances belong in the hands of a physician. Last updated: 2026-10-04.